pain

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

The firm has yet to publish peer-reviewed clinical evaluations, and genetics experts have raised doubts about its choice of targets to predict addiction. 

The companies plan to combine their platforms and research to launch new clinical assays and develop procedures and therapeutics to treat pain.

This Week in Nature

In Nature this week: short tandem repeats contribute to gene expression variation in humans, mutation linked to cold-aggravated peripheral pain, and more.

The effort has provided a comprehensive view of the toxin proteins involved in the sting of these dangerous jellyfish, which is now being used to identify targets for inhibitory drugs.

Homozygous recessive mutations in the gene PRDM12 appear to contribute to congenital insensitivity to pain by interfering with sensory nerve development.

The partners will work together to commercialize findings about the genetic basis of pain sensitivity and individual response to commonly prescribed pain medicines.

NEW YORK (GenomeWeb News) – Canada's government has awarded C$10 million (US$9.7 million) to fund a research program at McGill University focused on pain genetics that will be headed by Luda Diatchenko, McGill said yesterday.

Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.

Expressed RNAi drug developer Benitec Biopharma this week provided an update on its pipeline, stating that its two lead programs in cancer-associated neuropathic pain and drug-resistant lung cancer have fallen behind schedule as the company further optimizes its therapeutic candi

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Nature News writes that researchers are still wrangling over the role of the p-value.

In Nature this week: paternal age associated with de novo mutations in children, and more.